{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-202760","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.168373+00:00","generated_at":"2026-05-17T06:39:41.913007+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Monte Rosa and Novartis expand collaboration for immune-disease degraders; upfront $120M","bullets":["Monte Rosa receives $120M upfront from Novartis under new collaboration for degraders in immune-mediated diseases.","Up to $5.7B in total milestone payments plus tiered royalties (high single to low double-digits) across up to three programs.","Novartis gets exclusive license to one undisclosed discovery target and options on two additional preclinical I&I programs.","Second collaboration with Novartis; first (VAV1/MRT-6160) was announced Oct 2024.","Extended cash runway accelerates preclinical and clinical-stage immunology pipeline; Phase 2 readouts expected for MRT-8102, MRT-6160, MRT-2359."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-202760","json":"https://secwatch.observer/filing/0001193125-25-202760.json","markdown":"https://secwatch.observer/filing/0001193125-25-202760.md","text":"https://secwatch.observer/filing/0001193125-25-202760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000119312525202760/0001193125-25-202760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000119312525202760/glue-20250915.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:39:41.913007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}